Articles On Recce Pharmaceuticals (ASX:RCE)

The ASX 200 Health Index (XHJ) is trading lower by 1.40% at the time of writing, compared to the broader index which is down by 0.35%. Cell therapy specialist Chimeric Therapeutics (ASX:CHM) has just announced the final results of its Phase...

Recce Pharmaceuticals (RCE) doses the final three patients under cohort three of the Phase I intravenous (IV) clinical trial of RECCE327 (R327) The study is evaluating the safety and pharmacokinetics of R327 in seven to 10 subjects with do...

At the time of writing, the ASX 200 Health Index (XHJ) is down by 1.90%, while the benchmark ASX 200 has fallen by 0.3%. Genomics specialist Genetic Technologies (ASX:GTG) says that its laboratory in Fitzroy, Melbourne has received simultan...

“Completing this Cohort with the maximum number of subjects, sees R327 (500mg, I.V.) further a compelling Safety profile at a milestone dose. We anticipate recommendation to start dosing Cohort 4 at higher concentrations again in near weeks...

Recce Pharmaceuticals’ (RCE) phase-one intravenous clinical of R327 indicates a good safety and tolerability profile among seven healthy male subjects The company says its cohort three was tested with 500 mg of R327, which is designed for...

NeuroScientific Biopharmaceuticals (ASX:NSB) share price jumped ~13% today to 35 cents after an update on its lead drug candidate EmtinB. The company said it has executed on the successful completion of invitro genotoxicity and plasma prote...

According to PEW Charitable Trusts global antibiotic pipeline review, R327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.

Recce Pharmaceuticals (RCE) ended the December quarter with a cash balance of $15.83 million post research and development (R&D) costs of $1.54 million During the quarter, Recce reported positive data from its phase 1 and 2 clinical t...

The ASX 200 posted a small 0.11 fall on Tuesday, outperformed by the small end of town as the microcap Emerging Companies index rose by 0.66%. There were no clear catalysts as Asian markets struggled for direction after Wall Street was clos...

Recce Pharmaceuticals (RCE) has released positive safety data from its second cohort of subjects for its Phase I intravenous clinical trial of RECCE 327 (R327) R327 is designed to treat serious bacterial infections including sepsis. The se...

Key Points The Recce share price is up 3.85% to $1.35 An independent safety committee has cleared stronger dosing of Recce 327 Trial subjects are expected to be recruited sometime this week The Recce Pharmaceuticals Ltd (ASX: RCE) share...

According to PEW Charitable Trusts global antibiotic pipeline review, RECCE 327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.

The ASX has recovered following yesterday’s strong blow, closing up 1.29% with all 11 sectors finishing in the green on lower than normal trading volumes. Today’s biggest sector win was energy, up a nice 2.20% with the financial market foll...

Recce Pharmaceuticals (RCE) announces positive data from its phase one intravenous clinical trial for RECCE 327 (R327) R327 is designed to treat serious bacterial infections including sepsis In its first cohort of the phase one trial, nine...

According to PEW Charitable Trust, R327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.

Synthetic anti-infectives company Recce Pharmaceuticals (ASX:RCE) has announced it has recruited the first cohort of 10 healthy male subjects in its Phase I intravenous clinical trial of its lead compound.

R327 is administered as a single dose via a 1-hour IV infusion at a uniform rate, with all 80 subjects anticipated to have been dosed by the end of H1 2022.

Synthetic anti-infective company Recce Pharmaceuticals (ASX:RCE) has provided an update on its Phase I/II clinical trial for the treatment of burn wound infections.

Recce Pharmaceuticals’ share price has been boosted this morning on positive news about one of its drugs working on Perth patients with infected burns wounds.

“This initial update builds upon strong pre-clinical data demonstrating fast and efficient killing activity against common and problematic bacterial strains, and we are excited for the potential of R327 in the clinic," says CEO.

The ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader index which is down by 0.40%. The stock price of Neuren Pharmaceuticals (ASX:NEU) is up 100% this morning after the company announced its North...

Recce Pharmaceuticals (RCE) provides an update in the clinical trial of RECCE 327 (R327) for the treatment of burn wound infections RCE reports broad spectrum antibiotic activity on bacterial burn wound infections with a visible infection...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is soaring today. This comes after the pharmaceutical company provided an update on its clinical trial for the treatment of burn wound infections. At the time of writing, the Recce share...

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

In March this year, Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.

Receiving human ethics approval is a momentous achievement for Recce and the clinicians seeking effective treatments to combat antibiotic-resistant bacteria,” says chairman.

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327) The phase one trial is a randomised, placebo-controlled, ascending-dose, single-dose...

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is higher by 0.7%. Notices from both the Australian and European Patent Offices have been received by Noxopharm (ASX:NOX), relating to...

The misuse and overuse of antibiotics have led to the rapid growth of superbugs – a type of bacteria resistant to conventional treatments Serious infections such as pneumonia, tuberculosis and salmonella are becoming difficult to treat as...

The ASX retreated again as angst over inflation and the withdrawal of stimulus continued to weigh on global markets. The ASX 200 closed at 7,300 – 0.28% lower than Friday’s close. Tech was the biggest laggard, losing nearly 3% but energy an...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price was halted today after the company made a key announcement. Recce shares were trading 1.61% lower at 91.5 cents before being placed into a trading halt. Let’s get into the thick of it t...

The ASX had a positive end to the week with the ASX 200 gaining 0.87% today taking its weekly gain to 1.9%. All sectors gained with the best being resources which gained nearly 1.7%. Australia’s rise was in line with the broader Asia-Pacifi...

Superbugs that are resistant to antibiotics are causing an urgent global health crisis, but Recce Pharmaceuticals believes it has the solution.

Summary Northern Star (ASX:NST) reports strong June quarter, shares move up Santos (ASX:STO) jumps most in one month on lifting production, sales outlook Orocobre hits record high as lithium demand boosts production, pricing The S...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price ended the day higher after the company secured a patent in the United States. At the closing bell, the pharmaceutical company’s shares finished the day up 3.27% to $1.10. Let’s take a cl...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

The Aussie share market has fallen for two consecutive days, down by 0.46% today. Seven sectors were down, while four rose. Utilities and Mining were the worst peforming sectors, while Healtcare and IT were the best. In big cap news today,...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is on the move today. It comes after the pharmaceutical company provided a patent update on its synthetic anti-infectives. At the time of writing, the Recce share price is up 5.73% to $1...

RECCE® 327 (R327) has been shown to reduce deadly flesh-eating bacterial count below limit of quantification within 24 hours, at varying concentrations.

The Australian share market has followed Wall Street’s lead, closing 0.85% lower in today’s trading. All sectors were down except for Health Care, with the worst performers being Energy and Mining, both falling by more than 2%. In big cap n...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is falling after the company released an update on its clinical pipeline. In afternoon trade, shares in Recce Pharmaceuticals are trading 0.46% lower at $1.08. The update announced delay...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price has been a strong performer on Thursday. In afternoon trade, the biotechnology company’s shares are up 8.5% to $1.13. Why is the Recce share price surging higher? Investors have been bid...

Recce Pharmaceuticals (ASX:RCE), a company developing new classes of synthetic anti-infectives, has announced further results for its R327.

Following encouraging test results from stage1A and stage1B, RECCE® R327 received a qualified recommendation to advance to stage 2 of the program for further testing to be conducted by CSIRO.

The market is trading near day’s high at the close, after the Reserve Bank of Australia’s (RBA) maintained status quo in its latest policy announcement and upgraded the country’s GDP growth estimates. The benchmark index ASX 200 was up 35.5...

Summary Digital health player ResApp Health has entered into a non-exclusive distribution agreement with Ilara Health. Recce Pharmaceuticals stated that RECCE® 327 had shown bactericidal activity against ESKAPE pathogens, including the...

The Australian share market continued to trade in positive on Tuesday afternoon, owing to favourable global cues, with the benchmark index ASX 200 adding 21.9 points or 0.31% to trade at 7,050. Seven of 11 sectors were trading in green, wh...

ASX biotechs Recce Pharmaceuticals (ASX:RCE) and Botanix Pharmaceuticals (ASX:BOT) have this morning both given updates on their antimicrobial drug candidates as interest heats up on weapons to combat so-called “superbugs”. Recce said its s...